Pharma BD Deal Intelligence
A $11.7B all-cash acquisition (61% premium) meant to diversify CSL beyond plasma into iron-deficiency and nephrology, now a conceded failure: CSL booked $843M in impairments on Vifor/Seqirus intangibles and flagged ~$5B more through FY27, largely tied to Venofer's generic-competition hit.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
CSL acquired Vifor Pharma for $11.7B for iron deficiency, kidney, and cardio-renal diseases.
CSL CEO cited dampened near-term financial growth expectations for CSL Vifor due to CMS reimbursement bundling, generic Venofer competition, and lackluster…
CSL Vifor floated a 23M GBP settlement with UK Competition and Markets Authority over allegations it furnished doctors with misleading information about rival…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
CSL acquired Vifor Pharma for $11.7B in an all-cash tender offer ($179.25/share, 61% premium; closed 9 Aug 2022) to diversify beyond plasma into iron-deficiency, nephrology and cardio-renal disease. Post-close the thesis has deteriorated: at its 1H FY26 results (period ended 31 Dec 2025) CSL booked US$843M after-tax impairments on CSL Vifor and CSL Seqirus intangibles, with the Vifor portion largely tied to VENOFER after lower sales forecasts driven by generic competition. On 11 May 2026 interim CEO Gordon Naylor flagged a further ~US$5B in non-cash pre-tax impairments across FY26-FY27 (on top of US$1.5B at 1H FY26), explicitly including CSL Vifor intangibles and under-utilised property, plant and equipment, and cut FY26 guidance to ~US$15.2B revenue and ~US$3.1B NPATA. The write-downs represent CSL effectively conceding the Vifor deal has not delivered its original returns.
Veltassa (patiromer) competes in the chronic hyperkalemia market against one branded MOA analogue and a legacy incumbent. Non-absorbed potassium binders (novel): sodium zirconium cyclosilicate (Lokelma, AstraZeneca) is the direct franchise threat — FDA-approved May 2018, oral sachet, faster onset (~1 hour) and a sodium-based exchange resin with no calcium load. Lokelma has taken meaningful new-to-brand share in the US and holds preferred status on several Part D formularies. Legacy cation-exchange resins: sodium polystyrene sulfonate (Kayexalate, Concordia; generic) remains widely used despite black-box-level safety warnings around intestinal necrosis and is the dominant low-cost competitor in inpatient and Medicare fee-for-service; calcium polystyrene sulfonate (Kalimate, Kowa) is the ex-US analogue. Acute/adjunct therapies (different MOA class but displace binder use in ED/ICU): insulin+dextrose, beta-2 agonists (albuterol), sodium bicarbonate, and IV calcium gluconate are standard-of-care for acute hyperkalemia and reduce Veltassa's inpatient demand. Pipeline: several generics of patiromer and Lokelma are anticipated post-2027. For a commercial lead, Veltassa's near-term franchise threat is Lokelma's faster onset and lower pill burden in RAASi-enabled CKD/HF patients — the highest-value repeat-use segment.
Mircera (methoxy polyethylene glycol-epoetin beta) competes in the ESA market for anemia of chronic kidney disease, where the franchise threat is shaped by entrenched short-acting ESAs, HIF-PH inhibitors, and biosimilar pricing pressure. Short-acting ESAs: epoetin alfa (Epogen/Procrit, Amgen/Janssen) and biosimilars epoetin alfa-epbx (Retacrit, Pfizer) dominate US dialysis bundling and represent the primary volume competitor; Retacrit materially eroded reference Epogen share after 2018 launch. Long-acting ESAs: darbepoetin alfa (Aranesp, Amgen) is the direct MOA/dosing analogue to Mircera and holds the non-dialysis CKD segment in many markets; darbepoetin alfa-aafi biosimilar (Jesduvroq-unrelated — note Jesduvroq is HIF-PHI) pending. HIF-PH inhibitors: daprodustat (Jesduvroq, GSK) is FDA-approved (Feb 2023) for anemia in dialysis-dependent CKD only; roxadustat (Evrenzo, Astellas/FibroGen) approved in EU/Japan/China but rejected by FDA in 2021 on safety. Iron optimization adjuncts: ferric citrate (Auryxia, Akebia) and IV ferric carboxymaltose (Injectafer, CSL Vifor itself) reduce ESA dose requirements. For a commercial lead, Mircera's threat is bounded by Aranesp's incumbency in non-dialysis CKD and by the Fresenius-negotiated US dialysis supply deal that gave Mircera protected bundled access through 2024.
Injectafer/Ferinject (ferric carboxymaltose) competes in the IV iron market for iron deficiency anemia, where the franchise threat is defined by newer high-dose single-infusion agents and oral-iron generics. High-dose IV iron (single-dose analogues): ferumoxytol (Feraheme, Covis) and ferric derisomaltose (Monoferric, Pharmacosmos) are the most direct MOA competitors, each approved for single ~1000 mg infusions versus Injectafer's two-dose regimen; Monoferric launched in the US in 2020 and has taken share on convenience and a lower hypophosphatemia signal. Multi-dose IV iron: iron sucrose (Venofer, CSL Vifor) and sodium ferric gluconate (Ferrlecit, Sanofi/generic) remain the dialysis workhorses and dominate ESRD bundled volume. Iron isomaltoside/iron dextran: low-molecular-weight iron dextran (INFeD, Allergan) is an older test-dose product with anaphylaxis-limited use. Oral iron (different route): ferrous sulfate, ferrous fumarate, and ferric maltol (Accrufer, Shield) are first-line in non-dialysis IDA and cap IV conversion. Safety label updates: a 2023 FDA label change for Injectafer added a hypophosphatemia warning, creating share-loss risk versus Monoferric. For a commercial lead, Monoferric is the most acute franchise threat in the US non-dialysis IDA segment.
Secured 93.99% of shares with all regulatory clearances. Regulatory step in CSL Limited's acquisition process for Vifor Pharma Group.
CSL Limited completed its acquisition of Vifor Pharma Group for $11.7B. CSL acquired Vifor Pharma for $11.7B for iron deficiency, kidney, and cardio-renal diseases.
FY2025 sales $2.23B (up 12%). Ferinject leads but Venofer faces generics. Reflects financial performance following CSL Limited's $11.7B acquisition of Vifor Pharma Group.
Interim CEO Gordon Naylor flagged ~US$5B additional non-cash pre-tax impairments across FY26-FY27 (atop US$1.5B at 1H FY26), including CSL Vifor intangibles and under-utilised PP&E; FY26 guidance cut to ~US$15.2B revenue / ~US$3.1B NPATA.
Generating $2.2B+ but Venofer generics and Ferinject step-edits cloud outlook. Assessment of CSL Limited's $11.7B acquisition of Vifor Pharma Group and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| CSL Limited / Vifor Pharma Group (this deal) | 2021 | $11.7B | 58 |
| CSL Limited / Memo Therapeutics AG | 2026 | $328M | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Novo Holdings A/S / Catalent (manufacturing sites) | 2024 | $11.0B | 81 |
| AstraZeneca PLC / Bristol-Myers Squibb Company / Amylin diabetes alliance | 2012 | $3.5B | 77 |
← Browse all deals · How we score deals
More: 2021 deals · Metabolic deals